Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 5, 2015, Pages 509-514

  Mingot Castellano, María E ^a   González Díaz, Laura ^a   Tamayo Bermejo, Rocio ^a   Heiniger Mazo, Anabel I ^a  

^a University Regional Hospital   (Spain)

Author keywords

adherence; haemophilia A; on demand; pharmacokinetic; prophylaxis; trough levels

Indexed keywords

BLOOD CLOTTING FACTOR 8 DERIVATIVE; HEMOGLOBIN; PLASMA DERIVED BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII SQ;

ADULT; ANAPHYLAXIS; ARTICLE; BRAIN HEMORRHAGE; CASE STUDY; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; DEMOGRAPHY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; HEMARTHROSIS; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA A; HEMOPHILIC ARTHROPATHY; HUMAN; ISCHEMIA; LONG TERM CARE; MEDICATION COMPLIANCE; MUSCLE HEMATOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOEMBOLISM; FEMALE; MALE; METABOLISM; YOUNG ADULT;

ADULT; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; MALE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84941549410     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000261     Document Type: Article

References (23)

1. Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Ballieres Clin Haematol 1996; 9: 259-271
2. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-127
3. World Federation of Haemophilia (WFH). Haemophilia. Guidelines for the management of haemophilia, 2nd edition Montréal, Québec: Blackwell Publishing Ltd; 2012
4. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl 1): 1-4
5. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe haemophilia. Am J Hematol 1994; 47: 113-117
6. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399
7. Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #179. New York: National Hemophilia Foundation, May 19, 2001
8. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylaxis vs. on demand sucrose-formulated recombinant factor VIII treatment in adults with severe haemophilia A: results from a 13-month cross-over study. J Thromb Haemost 2010; 8: 83-89
9. Manco-Johnson M, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe haemophilia A (SPINART). J Throm Haemost 2013; 11: 1119-1127
10. Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-173
11. Gringieri A, Lambert T, Street A, Aledort L. Tertiary prophylaxis in adults: is there a rationale? Haemophilia 2012; 18: 722-728
12. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-582
13. Aznar JA, Carcia-Dasi M, Perez-Alenda S, Marco A, Jaca M, Moret A, Querol F. Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre. Vox Sang 2014; 106: 68-74
14. Collins P, Blanchette V, Fisher K, Bjorkman S, Fritsch S, Schroth P, et al. Break-Trough bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-420
15. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 49: 153-159
16. Centers for Disease Control and Prevention. Report on the universal data collection program: includes data collected from May 1998 trough December 2004. Atlanta, Georgia; 2005 Jul. Report No.: Volume 7; Number 1
17. Fischer K, van der Bom JG, Negrier C, Mauser-Bunschoten EP, Roosendaal G, et al. Prophylactic vs. on-demand treatment strategies for severe haemophilia: a comparison of costs and long-Term outcomes. Haemophilia 2002; 8: 745-752
18. Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-951
19. Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in haemophilia A management. J Thromb Haemost 2012; 10: 359-367
20. Colombo GL, Di Matteo S, Mancuso ME. Cost-utility analysis of prophylaxis versus treatment on demand in severe haemophilia A. Clinic Econ Outcomes Res 2011; 3: 55-61
21. Van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-Term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-112
22. Ho S, Gue D, McIntosh K, Bucevska M, Yang M, Jackson S. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia. Haemophilia 2014; 20: 39-43
23. World Health Organization Report. Adherence to long-Term therapies: evidence for action. 2003. http: //www.who.int/chp/knowledge/publications/adherence-full-report.pdf